Tagged with BI

Saudi Arabia Trad Alkhelaiwi lays out the scale of Johnson & Johnson’s transformation in Saudi Arabia, particularly the transition to a direct model in the medtech space, reflecting the company’s long-term commitment to the country’s healthcare sector. Alkhelaiwi also explains how Johnson & Johnson’s solutions in Saudi Arabia are tailored to address…

Saudi Arabia Lifera was established in 2023 to address key priorities outlined in the National Biotech Strategy of Saudi Arabia, focusing on improving biopharma resilience and enabling the development of biologics, vaccines, cell and gene therapies, and other advanced medical therapeutics. The organisation’s first chairman, Ibrahim Aljuffali, explains how Lifera aims to…

Saudi Arabia Karim Smaira and Kamel Ghammachi, founders of Genpharm, underscores the strategic significance of the recent majority acquisition by Abdul Latif Jameel Health, part of Abdul Latif Jameel, driven by a shared vision and the imperative for accelerated growth. They discuss their expansion into diverse therapeutic areas, emphasizing the importance of…

Saudi Arabia aljeel, a leading Saudi family-owned medtech distributor, has undergone a structural transformation in recent years and today attempts to maintain the dynamism of a family business while incorporating the structured processes of a publicly traded entity. Now CEO of the firm, AbdulGhani El-Ajou touches on some of aljeel’s key initiatives,…

Global Having been quietly working away on its mRNA platform for years, Moderna stepped into the limelight during the COVID-19 pandemic and became a commercial-stage outfit almost overnight with its vaccine. After generating sales of USD 18.4 billion in 2022, demand for the company’s Spikevax shot, still its only commercialized product…

Switzerland While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022 slump, the latest report from the Swiss Biotech Association and EY shows the sector’s resilience with the record revenues of…

Hong Kong VMS Group was founded in 2006 and since then has built close relationships with a handful of large anchor investors, including some of the largest families in Hong Kong. Apart from managing over USD 4.3 billion across its three in-house strategies – Private Equity, Real Estate and Structured Finance, it…

China In recent years, global pharma’s Business Development (BD) operations in Asia have evolved from primarily managing global agreements locally to engaging in more complex tasks like contract negotiation and due diligence. Servier’s Asia BD Head Cynthia Xin Wang explains how this shift reflects changing market dynamics and the growing importance…

China Since it was established in 1988,  PhIRDA, an organization that groups together China’s pharma innovators, research institutions and investors has played an active role in the evolution of China’s biopharma landscape. Executive President Prof. Song Ruilin outlines the advances and some of the challenges and opportunities facing China’s biotech and…

Saudi Arabia Baxter Saudia Arabia GM Faisal BinDail shares some insights into the renal care specialist’s local manufacturing hub, the sole manufacturing site for peritoneal dialysis products in the Middle East, and the company’s plans to expand its reach in Saudi Arabia and the broader region.   We aim to provide our…

Saudi Arabia Basel Al-Qahtani, General Manager of Boston Scientific Saudi Arabia, discusses how Boston Scientific has expanded its operations to establish a fully fledged regional headquarters in the kingdom. He outlines the company’s commitment to Saudi Arabia’s Vision 2030 agenda through public-private partnerships and potentially through accountable care organizations, and underlines the…

Saudi Arabia Since joining Moderna as its first ex-US commercial employee in Spring 2020, Dan Staner has played a leading role in developing what is now one of the world’s top 20 biggest pharma companies. Speaking exclusively to PharmaBoardroom, Staner describes how Moderna has been able to fashion a new, optimised company…